CD19, CD20 and CD22 MAbs

CD19, CD20 and CD22 are B-cell lineage-specific molecules involved in immune regulation. Preclinical studies indicate that antibodies targeting these antigens may block B-cell activities that are associated with many tumors and autoimmune diseases, including multiple myeloma, B-cell lymphomas, rheumatoid arthritis, and lupus. Early research on the potential therapeutic benefits of blocking these molecules has been conducted by Thomas F. Tedder, Ph.D., chairman of the Department of Immunology at Duke University Medical Center and leading authority in B-cell biology.